Planet 13 Holdings (PLNH) Change in Accured Expenses (2022 - 2026)
Planet 13 Holdings (PLNH) posted quarterly Change in Accured Expenses of -$1.4 million for Q1 2026, down 1682.93% year-over-year from $86673.0 in Q1 2025, and down 237.01% quarter-over-quarter from -$407100.0 in Q3 2025.
Planet 13 Holdings (PLNH) Change in Accured Expenses (2022 - 2026) Analysis & Trends
Planet 13 Holdings (PLNH) has reported Change in Accured Expenses for 5 consecutive years, with -$1.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 1682.93% year-over-year to -$1.4 million; the TTM figure through Mar 2026 stood at -$1.4 million (up 27.75% YoY), while the FY2024 annual figure was -$2.9 million, down 50.95% from the prior year.
- Change in Accured Expenses slipped to -$1.4 million in Q1 2026 per PLNH's latest filing, from -$407100.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $1.9 million in Q4 2022 and bottomed at -$3.7 million in Q4 2024.
- Historically, Change in Accured Expenses has averaged -$347332.9 across 5 years, with a median of -$300374.5 in 2023.
- On a YoY basis, Change in Accured Expenses climbed as much as 194.14% in 2024 and fell as far as 1796.43% in 2024.
- Planet 13 Holdings' Change in Accured Expenses stood at $1.9 million in 2022, then sank by 110.0% to -$193649.0 in 2023, then tumbled by 1796.43% to -$3.7 million in 2024, then soared by 88.91% to -$407100.0 in 2025, then slumped by 237.01% to -$1.4 million in 2026.
- Business Quant data shows PLNH's Change in Accured Expenses at -$1.4 million in Q1 2026, -$407100.0 in Q3 2025, and $318755.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 82.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 142.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -219.00 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | -4.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -8.50 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Planet 13 Holdings | 50.16 Mn | 33.68 Mn | 12.32 Mn | 1.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.14 Mn |
| Jun 30, 2026 | 1.14 Mn |
| Mar 31, 2026 | -1.37 Mn |
| Mar 31, 2026 | -1.37 Mn |
| Sep 30, 2025 | -407,100.00 |
| Sep 30, 2025 | -407,100.00 |
| Jun 30, 2025 | 318,755.00 |
| Jun 30, 2025 | 318,755.00 |
| Mar 31, 2025 | 86,673.00 |
| Mar 31, 2025 | 86,673.00 |
| Dec 31, 2024 | -3.67 Mn |
| Dec 31, 2024 | -3.67 Mn |
| Sep 30, 2024 | 632,052.00 |
| Sep 30, 2024 | 632,052.00 |
| Jun 30, 2024 | 1.05 Mn |
| Jun 30, 2024 | 1.05 Mn |
| Mar 31, 2024 | -956,061.00 |
| Mar 31, 2024 | -956,061.00 |
| Dec 31, 2023 | -193,649.00 |
| Dec 31, 2023 | -193,649.00 |